Literature DB >> 12506776

Laboratory testing in the diagnosis and management of idiopathic inflammatory myopathies.

Ira N Targoff1.   

Abstract

Laboratory testing commonly used to assess the idiopathic inflammatory myopathies (IIMs) can be divided into three categories: (1) measurement of serum activities or concentrations of muscle-derived factors--such as enzymes, myoglobin, and other molecules--in order to assess muscle injury; (2) immunologic tests that detect markers of the disease process, including serum autoantibodies that have been associated with myositis; and (3) general laboratory tests that are used to assess the patient's general status and medical condition. The laboratory assessment of muscle-derived factors that reflect muscle injury, and the determination of serum autoantibodies, play valuable roles in the diagnosis and management of the IIM. Enzyme elevations do not correlate with disease activity in all patients, however, and they must be interpreted within the clinical context. Autoantibodies can identify disease subsets with distinctive patterns of clinical manifestations, genetics, responses to therapy and prognosis, but disease-specific autoantibodies are present in only half of patients with IIM. Recent studies have defined additional myositis autoantibodies that may improve our capacity to diagnose and manage the IIM.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12506776     DOI: 10.1016/s0889-857x(02)00032-7

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN: 0889-857X            Impact factor:   2.670


  33 in total

1.  A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy.

Authors:  Lisa Christopher-Stine; Livia A Casciola-Rosen; Grace Hong; Tae Chung; Andrea M Corse; Andrew L Mammen
Journal:  Arthritis Rheum       Date:  2010-09

Review 2.  Myositis-related interstitial lung disease and antisynthetase syndrome.

Authors:  Joshua Solomon; Jeffrey J Swigris; Kevin K Brown
Journal:  J Bras Pneumol       Date:  2011 Jan-Feb       Impact factor: 2.624

3.  Anti-melanoma differentiation-associated protein 5-associated dermatomyositis: expanding the clinical spectrum.

Authors:  John C Hall; Livia Casciola-Rosen; Lesly-Ann Samedy; Jessie Werner; Kristie Owoyemi; Sonye K Danoff; Lisa Christopher-Stine
Journal:  Arthritis Care Res (Hoboken)       Date:  2013-08       Impact factor: 4.794

Review 4.  Autoimmune myopathies: autoantibodies, phenotypes and pathogenesis.

Authors:  Andrew L Mammen
Journal:  Nat Rev Neurol       Date:  2011-06-08       Impact factor: 42.937

5.  The Diagnosis and Treatment of Antisynthetase Syndrome.

Authors:  Leah J Witt; James J Curran; Mary E Strek
Journal:  Clin Pulm Med       Date:  2016-09

6.  Autoantibodies and their significance in myositis.

Authors:  Ira N Targoff
Journal:  Curr Rheumatol Rep       Date:  2008-08       Impact factor: 4.592

7.  Expression of the dermatomyositis autoantigen Mi-2 in regenerating muscle.

Authors:  Andrew L Mammen; Livia A Casciola-Rosen; John C Hall; Lisa Christopher-Stine; Andrea M Corse; Antony Rosen
Journal:  Arthritis Rheum       Date:  2009-12

8.  Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis.

Authors:  Rohit Aggarwal; Andriy Bandos; Ann M Reed; Dana P Ascherman; Richard J Barohn; Brian M Feldman; Frederick W Miller; Lisa G Rider; Michael O Harris-Love; Marc C Levesque; Chester V Oddis
Journal:  Arthritis Rheumatol       Date:  2014-03       Impact factor: 10.995

Review 9.  Clinical interpretation of antinuclear antibody tests in systemic rheumatic diseases.

Authors:  Minoru Satoh; Monica Vázquez-Del Mercado; Edward K L Chan
Journal:  Mod Rheumatol       Date:  2009-03-10       Impact factor: 3.023

10.  Brief report: antisynthetase syndrome-associated myocarditis.

Authors:  Kavita Sharma; Ana-Maria Orbai; Dipan Desai; Oscar H Cingolani; Marc K Halushka; Lisa Christopher-Stine; Andrew L Mammen; Katherine C Wu; Sammy Zakaria
Journal:  J Card Fail       Date:  2014-07-29       Impact factor: 5.712

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.